Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants

针对SARS-CoV-2多种变种的刺突蛋白RBM特异性人类抗体的结构基础

阅读:4
作者:Kiyomi Shitaoka # ,Akifumi Higashiura # ,Yohei Kawano # ,Akima Yamamoto ,Yoko Mizoguchi ,Takao Hashiguchi ,Norihisa Nishimichi ,Shiyu Huang ,Ayano Ito ,Shun Ohki ,Miyuki Kanda ,Tomohiro Taniguchi ,Rin Yoshizato ,Hitoshi Azuma ,Yasuo Kitajima ,Yasuyuki Yokosaki ,Satoshi Okada ,Takemasa Sakaguchi ,Tomoharu Yasuda

Abstract

The decrease of antibody efficacy to mutated SARS-CoV-2 spike RBD explains the breakthrough infections and reinfections by Omicron variants. Here, we analyzed broadly neutralizing antibodies isolated from long-term hospitalized convalescent patients of early SARS-CoV-2 strains. One of the antibodies named NCV2SG48 is highly potent to broad SARS-CoV-2 variants including Omicron BA.1, BA.2, and BA.4/5. To reveal the mode of action, we determined the sequence and crystal structure of the Fab fragment of NCV2SG48 in a complex with spike RBD from the original, Delta, and Omicron BA.1. NCV2SG48 is from a minor VH but the multiple somatic hypermutations contribute to a markedly extended binding interface and hydrogen bonds to interact with conserved residues at the core receptor-binding motif of RBD, which efficiently neutralizes a broad spectrum of variants. Thus, eliciting the RBD-specific B cells to the longitudinal germinal center reaction confers potent immunity to broad SARS-CoV-2 variants emerging one after another.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。